Alliance A021804: A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide versus Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma
      Google Scholar   
Citation:
J Clin Oncol vol 41 (suppl 16) TPS4191
Meeting Instance:
ASCO 2023
Year:
2023
Type:
Abstract
Sub type:
Poster Discussion
Funding:
NCTN
Endpoint:
No-Endpoint
Analysis:
Trial-Description-Only
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U24CA196171, U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888 (SWOG)  
Corr. Author:
 
Authors:
                             
Networks:
LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-UT003, MCRC, MD001, OR013   
Study
Alliance-A021804
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: